TNF and lymphoma: Small-molecule inhibitors (tofacitinib) and biologic therapies such as anti-TNF, anti-integrin, and anti-IL-12/23 can increase susceptibility to infections (e.g., tuberculosis, opportunistic fungal infections) and, in rare cases, lead to the development of lymphomas or demyelinating disorders [114,119].